Eupraxia Pharmaceuticals
EPRX
9 hedge funds and large institutions have $5.63M invested in Eupraxia Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
24% more capital invested
Capital invested by funds: $4.55M → $5.63M (+$1.09M)
13% more funds holding
Funds holding: 8 → 9 (+1)
0.08% more ownership
Funds ownership: 5.05% → 5.13% (+0.08%)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$35.1K |
| 2 |
Millennium Management
New York
|
+$29.6K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$22.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$14.8K |
| 2 |
SC
Scotia Capital
Toronto,
Ontario, Canada
|
-$13.5K |
| 3 |
1WA
180 Wealth Advisors
Federal Way,
Washington
|
-$7.4K |
| 4 |
TWC
TD Waterhouse Canada
Toronto,
Ontario, Canada
|
-$3.83K |
| 5 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$317 |
EPRX Hedge Fund Activity: Q4 2024 in Review
9 of the 7,608 institutional investors tracked by Wall St. Rank reported a position in Eupraxia Pharmaceuticals (EPRX) for Q4 2024, worth a combined $5.63M — up 24% from $4.55M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new EPRX positions and 1 closed out — a net gain of 1 holder — while 2 added to existing stakes and 4 trimmed.
The largest buyer was Royal Bank of Canada, adding an estimated $35.1K. The largest seller was UBS Group, cutting an estimated $14.8K.
- 9 institutional investors held Eupraxia Pharmaceuticals (EPRX) as of Q4 2024, up from 8 in Q3 2024.
- Funds reported $5.63M of Eupraxia Pharmaceuticals stock for Q4 2024, up 24% quarter-over-quarter.
- 2 funds opened new Eupraxia Pharmaceuticals positions in Q4 2024 and 1 closed out, a net change of +1 holder.
- The largest Eupraxia Pharmaceuticals buyer in Q4 2024 was Royal Bank of Canada, an estimated $35.1K added.
- The largest Eupraxia Pharmaceuticals seller in Q4 2024 was UBS Group, an estimated $14.8K sold.
Based on aggregated 13F filings for Q4 2024.